4-1BBL/TNFSF9 蛋白, Cynomolgus (HEK293, Fc)

4-1BBL (4-1BB ligand) is a type II membrane protein of the TNF superfamily, is expressed on antigen-presenting cells. 4-1BB with 4-1BBL can induce T-cell expansion, cytokine induction, differentiation, and upregulation of anti-apoptotic genes as well as protect T cells from activation-induced cell death (AICD)^[1]. 4-1BBL stimulates T cell proliferation and induces effective anti-tumor immune responses^[3]. 4-1BBL is an immunostimulant molecule that interacts with the 4-1BB high-affinity receptor during the antigen presentation, providing costimulatory signals to both CD4+ and CD8+ T cells through the activation of NF-kB, c-Jun, and p38 downstream pathways, triggering pleiotropic effects on the immune system^[4]. 4-1BBL/TNFSF9 Protein, Cynomolgus (HEK293, Fc) is a recombinant protein with a N-Terminal Fc label, It consists of 184 amino acids (R68-E251) and is produced in HEK293 cells.

4-1BBL 在多种抗原呈递细胞 (APC) 上表达，包括活化的 B 细胞、树突状细胞、巨噬细胞和骨髓细胞^[1]。
人类的氨基酸序列4-1BBL蛋白与小鼠和大鼠4-1BBL蛋白同源性较低。
4-1BBL与高亲和力的4-1BB结合，导致细胞内TRAF接头分子（TRAF1和TRAF2）的募集，然后激活NF-jB 和细胞外信号调节激酶 (ERK)、c-Jun N 末端激酶 (JNK) 和 p38 丝裂原相关蛋白 (MAP) 激酶信号级联反应。4-1BBL 与 4-1BB 的结合会在 T 细胞中产生强烈的共刺激信号，从而导致抗凋亡分子上调、细胞因子分泌和效应功能增强^[2]。
4-1BBL 是 TNF 蛋白家族的成员。4-1BBL是一种免疫刺激分子，在抗原呈递过程中与4-1BB高亲和力受体相互作用，通过激活NF-kB、c-Jun和p38下游通路向CD4+和CD8+T细胞提供共刺激信号，触发对免疫系统的多效性作用^[4]。4-1BBL 显着诱导 T 细胞增殖并增加 IL-2 和 IFN-γ^[5] 的刺激。

Cynomolgus

HEK293

N-hFc

XP_015296398 (R68-E251)

102129676  [NCBI]

Approximately 47.8 kDa.

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Li Y, et al. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Rep. 2018 Oct 23;25(4):909-920.e4.  [Content Brief]

  [2]. Bitra A, et al. Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding. J Biol Chem. 2019 Feb 8;294(6):1831-1845.  [Content Brief]

  [3]. Meseck M, et al. A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother. 2011 Mar;34(2):175-82.

  [4]. Martinez-Perez AG, et al. 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer. Int J Mol Sci. 2021 Jun 9;22(12):6210.  [Content Brief]

  [5]. Salih HR, et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol. 2001 Oct 1;167(7):4059-66.  [Content Brief]